ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Influenza (Flu) Antiviral Drugs Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-32Y5762
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global and United States Influenza Flu Antiviral Drugs Market Report Forecast 2022 2028
BUY CHAPTERS

Global Influenza (Flu) Antiviral Drugs Market Research Report 2025

Code: QYRE-Auto-32Y5762
Report
July 2025
Pages:115
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Roche
Sanofi
Johnson & Johnson
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline(GSK )
Amgen Inc
Astrazeneca plc
Bristol–Myers Squibb
Eli Lilly
TEVA
Bayer
Novo Nordisk
Allergan plc
Takeda
Boehringer Ingelheim
Merck
Teva Pharmaceutical Industries
Mylan NV
F.Hoffmann-La Roche
Aurobindo Pharma
Cipla Ltd
Johnson & Johnson

Influenza (Flu) Antiviral Drugs Market Size

The global market for Influenza (Flu) Antiviral Drugs was valued at US$ 1080 million in the year 2024 and is projected to reach a revised size of US$ 1464 million by 2031, growing at a CAGR of 4.5% during the forecast period.

Influenza (Flu) Antiviral Drugs Market

Influenza (Flu) Antiviral Drugs Market

Antiviral drugs are a class of drugs for the specific treatment of viral infections.
The global pharmaceutical market is 1475 billion US$ in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion US$ in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Influenza (Flu) Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza (Flu) Antiviral Drugs.
The Influenza (Flu) Antiviral Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenza (Flu) Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza (Flu) Antiviral Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Influenza (Flu) Antiviral Drugs Market Report

Report Metric Details
Report Name Influenza (Flu) Antiviral Drugs Market
Accounted market size in year US$ 1080 million
Forecasted market size in 2031 US$ 1464 million
CAGR 4.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Household
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Roche, Sanofi, Johnson & Johnson, Merck, Novartis, AbbVie, Gilead Sciences, GlaxoSmithKline (GSK), Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva, Bayer, Novo Nordisk, Allergan, Takeda, Boehringer Ingelheim, Teva Pharmaceutical Industries, Mylan, F. Hoffmann-La Roche, Bristol-Myers-Squibb, Aurobindo Pharma, Cipla
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Influenza (Flu) Antiviral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Influenza (Flu) Antiviral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Influenza (Flu) Antiviral Drugs Market growing?

Ans: The Influenza (Flu) Antiviral Drugs Market witnessing a CAGR of 4.5% during the forecast period 2025-2031.

What is the Influenza (Flu) Antiviral Drugs Market size in 2031?

Ans: The Influenza (Flu) Antiviral Drugs Market size in 2031 will be US$ 1464 million.

Who are the main players in the Influenza (Flu) Antiviral Drugs Market report?

Ans: The main players in the Influenza (Flu) Antiviral Drugs Market are Pfizer, Roche, Sanofi, Johnson & Johnson, Merck, Novartis, AbbVie, Gilead Sciences, GlaxoSmithKline (GSK), Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva, Bayer, Novo Nordisk, Allergan, Takeda, Boehringer Ingelheim, Teva Pharmaceutical Industries, Mylan, F. Hoffmann-La Roche, Bristol-Myers-Squibb, Aurobindo Pharma, Cipla

What are the Application segmentation covered in the Influenza (Flu) Antiviral Drugs Market report?

Ans: The Applications covered in the Influenza (Flu) Antiviral Drugs Market report are Hospital, Clinic, Household, Others

What are the Type segmentation covered in the Influenza (Flu) Antiviral Drugs Market report?

Ans: The Types covered in the Influenza (Flu) Antiviral Drugs Market report are Penetration and Dehulling Inhibitors, DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protein Inhibitors, Neuraminidase Inhibitors, Broad-spectrum Antiviral Drugs

Recommended Reports

Influenza / Flu Markets

Antiviral & Infectious

Anti-Infective Therapies

1 Influenza (Flu) Antiviral Drugs Market Overview
1.1 Product Definition
1.2 Influenza (Flu) Antiviral Drugs by Type
1.2.1 Global Influenza (Flu) Antiviral Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Penetration and Dehulling Inhibitors
1.2.3 DNA Polymerase Inhibitors
1.2.4 Reverse Transcriptase Inhibitors
1.2.5 Protein Inhibitors
1.2.6 Neuraminidase Inhibitors
1.2.7 Broad-spectrum Antiviral Drugs
1.3 Influenza (Flu) Antiviral Drugs by Application
1.3.1 Global Influenza (Flu) Antiviral Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household
1.3.5 Others
1.4 Global Influenza (Flu) Antiviral Drugs Market Size Estimates and Forecasts
1.4.1 Global Influenza (Flu) Antiviral Drugs Revenue 2020-2031
1.4.2 Global Influenza (Flu) Antiviral Drugs Sales 2020-2031
1.4.3 Global Influenza (Flu) Antiviral Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Influenza (Flu) Antiviral Drugs Market Competition by Manufacturers
2.1 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Influenza (Flu) Antiviral Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Influenza (Flu) Antiviral Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Influenza (Flu) Antiviral Drugs, Product Type & Application
2.7 Global Key Manufacturers of Influenza (Flu) Antiviral Drugs, Date of Enter into This Industry
2.8 Global Influenza (Flu) Antiviral Drugs Market Competitive Situation and Trends
2.8.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Influenza (Flu) Antiviral Drugs Players Market Share by Revenue
2.8.3 Global Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Influenza (Flu) Antiviral Drugs Market Scenario by Region
3.1 Global Influenza (Flu) Antiviral Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2020-2031
3.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2020-2025
3.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2026-2031
3.3 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2020-2031
3.3.1 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2020-2025
3.3.2 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2026-2031
3.4 North America Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
3.4.1 North America Influenza (Flu) Antiviral Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Influenza (Flu) Antiviral Drugs Sales by Country (2020-2031)
3.4.3 North America Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
3.5.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Influenza (Flu) Antiviral Drugs Sales by Country (2020-2031)
3.5.3 Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Influenza (Flu) Antiviral Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Influenza (Flu) Antiviral Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
3.7.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Influenza (Flu) Antiviral Drugs Sales by Country (2020-2031)
3.7.3 Latin America Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2020-2031)
4.1.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2020-2025)
4.1.2 Global Influenza (Flu) Antiviral Drugs Sales by Type (2026-2031)
4.1.3 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2020-2031)
4.2 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2020-2031)
4.2.1 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2020-2025)
4.2.2 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2026-2031)
4.2.3 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Influenza (Flu) Antiviral Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2020-2031)
5.1.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2020-2025)
5.1.2 Global Influenza (Flu) Antiviral Drugs Sales by Application (2026-2031)
5.1.3 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2020-2031)
5.2 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2020-2031)
5.2.1 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2020-2025)
5.2.2 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2026-2031)
5.2.3 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Influenza (Flu) Antiviral Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Influenza (Flu) Antiviral Drugs Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Company Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Merck
6.5.1 Merck Company Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck Influenza (Flu) Antiviral Drugs Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Company Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 AbbVie
6.7.1 AbbVie Company Information
6.7.2 AbbVie Description and Business Overview
6.7.3 AbbVie Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
6.7.5 AbbVie Recent Developments/Updates
6.8 Gilead Sciences
6.8.1 Gilead Sciences Company Information
6.8.2 Gilead Sciences Description and Business Overview
6.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
6.8.5 Gilead Sciences Recent Developments/Updates
6.9 GlaxoSmithKline (GSK)
6.9.1 GlaxoSmithKline (GSK) Company Information
6.9.2 GlaxoSmithKline (GSK) Description and Business Overview
6.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
6.9.5 GlaxoSmithKline (GSK) Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Company Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
6.10.5 Amgen Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Company Information
6.11.2 AstraZeneca Description and Business Overview
6.11.3 AstraZeneca Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
6.12 Bristol-Myers Squibb
6.12.1 Bristol-Myers Squibb Company Information
6.12.2 Bristol-Myers Squibb Description and Business Overview
6.12.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
6.12.5 Bristol-Myers Squibb Recent Developments/Updates
6.13 Eli Lilly
6.13.1 Eli Lilly Company Information
6.13.2 Eli Lilly Description and Business Overview
6.13.3 Eli Lilly Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
6.13.5 Eli Lilly Recent Developments/Updates
6.14 Teva
6.14.1 Teva Company Information
6.14.2 Teva Description and Business Overview
6.14.3 Teva Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Teva Influenza (Flu) Antiviral Drugs Product Portfolio
6.14.5 Teva Recent Developments/Updates
6.15 Bayer
6.15.1 Bayer Company Information
6.15.2 Bayer Description and Business Overview
6.15.3 Bayer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
6.15.5 Bayer Recent Developments/Updates
6.16 Novo Nordisk
6.16.1 Novo Nordisk Company Information
6.16.2 Novo Nordisk Description and Business Overview
6.16.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
6.16.5 Novo Nordisk Recent Developments/Updates
6.17 Allergan
6.17.1 Allergan Company Information
6.17.2 Allergan Description and Business Overview
6.17.3 Allergan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
6.17.5 Allergan Recent Developments/Updates
6.18 Takeda
6.18.1 Takeda Company Information
6.18.2 Takeda Description and Business Overview
6.18.3 Takeda Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
6.18.5 Takeda Recent Developments/Updates
6.19 Boehringer Ingelheim
6.19.1 Boehringer Ingelheim Company Information
6.19.2 Boehringer Ingelheim Description and Business Overview
6.19.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
6.19.5 Boehringer Ingelheim Recent Developments/Updates
6.20 Teva Pharmaceutical Industries
6.20.1 Teva Pharmaceutical Industries Company Information
6.20.2 Teva Pharmaceutical Industries Description and Business Overview
6.20.3 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
6.20.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.21 Mylan
6.21.1 Mylan Company Information
6.21.2 Mylan Description and Business Overview
6.21.3 Mylan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
6.21.5 Mylan Recent Developments/Updates
6.22 F. Hoffmann-La Roche
6.22.1 F. Hoffmann-La Roche Company Information
6.22.2 F. Hoffmann-La Roche Description and Business Overview
6.22.3 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.22.4 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
6.22.5 F. Hoffmann-La Roche Recent Developments/Updates
6.23 Bristol-Myers-Squibb
6.23.1 Bristol-Myers-Squibb Company Information
6.23.2 Bristol-Myers-Squibb Description and Business Overview
6.23.3 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
6.23.5 Bristol-Myers-Squibb Recent Developments/Updates
6.24 Aurobindo Pharma
6.24.1 Aurobindo Pharma Company Information
6.24.2 Aurobindo Pharma Description and Business Overview
6.24.3 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
6.24.5 Aurobindo Pharma Recent Developments/Updates
6.25 Cipla
6.25.1 Cipla Company Information
6.25.2 Cipla Description and Business Overview
6.25.3 Cipla Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2020-2025)
6.25.4 Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
6.25.5 Cipla Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Influenza (Flu) Antiviral Drugs Industry Chain Analysis
7.2 Influenza (Flu) Antiviral Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Influenza (Flu) Antiviral Drugs Production Mode & Process Analysis
7.4 Influenza (Flu) Antiviral Drugs Sales and Marketing
7.4.1 Influenza (Flu) Antiviral Drugs Sales Channels
7.4.2 Influenza (Flu) Antiviral Drugs Distributors
7.5 Influenza (Flu) Antiviral Drugs Customer Analysis
8 Influenza (Flu) Antiviral Drugs Market Dynamics
8.1 Influenza (Flu) Antiviral Drugs Industry Trends
8.2 Influenza (Flu) Antiviral Drugs Market Drivers
8.3 Influenza (Flu) Antiviral Drugs Market Challenges
8.4 Influenza (Flu) Antiviral Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Roche
Sanofi
Johnson & Johnson
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline(GSK )
Amgen Inc
Astrazeneca plc
Bristol–Myers Squibb
Eli Lilly
TEVA
Bayer
Novo Nordisk
Allergan plc
Takeda
Boehringer Ingelheim
Merck
Teva Pharmaceutical Industries
Mylan NV
F.Hoffmann-La Roche
Aurobindo Pharma
Cipla Ltd
Johnson & Johnson
List of Tables
 Table 1. Global Influenza (Flu) Antiviral Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Influenza (Flu) Antiviral Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Influenza (Flu) Antiviral Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Influenza (Flu) Antiviral Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Influenza (Flu) Antiviral Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Influenza (Flu) Antiviral Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Influenza (Flu) Antiviral Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Influenza (Flu) Antiviral Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Influenza (Flu) Antiviral Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Influenza (Flu) Antiviral Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Influenza (Flu) Antiviral Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Influenza (Flu) Antiviral Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Influenza (Flu) Antiviral Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Influenza (Flu) Antiviral Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Influenza (Flu) Antiviral Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Influenza (Flu) Antiviral Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Influenza (Flu) Antiviral Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Influenza (Flu) Antiviral Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Influenza (Flu) Antiviral Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Influenza (Flu) Antiviral Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Influenza (Flu) Antiviral Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Influenza (Flu) Antiviral Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Influenza (Flu) Antiviral Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Influenza (Flu) Antiviral Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Influenza (Flu) Antiviral Drugs Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Roche Influenza (Flu) Antiviral Drugs Product
 Table 79. Roche Recent Developments/Updates
 Table 80. Sanofi Company Information
 Table 81. Sanofi Description and Business Overview
 Table 82. Sanofi Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Sanofi Influenza (Flu) Antiviral Drugs Product
 Table 84. Sanofi Recent Developments/Updates
 Table 85. Johnson & Johnson Company Information
 Table 86. Johnson & Johnson Description and Business Overview
 Table 87. Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product
 Table 89. Johnson & Johnson Recent Developments/Updates
 Table 90. Merck Company Information
 Table 91. Merck Description and Business Overview
 Table 92. Merck Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Merck Influenza (Flu) Antiviral Drugs Product
 Table 94. Merck Recent Developments/Updates
 Table 95. Novartis Company Information
 Table 96. Novartis Description and Business Overview
 Table 97. Novartis Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Novartis Influenza (Flu) Antiviral Drugs Product
 Table 99. Novartis Recent Developments/Updates
 Table 100. AbbVie Company Information
 Table 101. AbbVie Description and Business Overview
 Table 102. AbbVie Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. AbbVie Influenza (Flu) Antiviral Drugs Product
 Table 104. AbbVie Recent Developments/Updates
 Table 105. Gilead Sciences Company Information
 Table 106. Gilead Sciences Description and Business Overview
 Table 107. Gilead Sciences Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Gilead Sciences Influenza (Flu) Antiviral Drugs Product
 Table 109. Gilead Sciences Recent Developments/Updates
 Table 110. GlaxoSmithKline (GSK) Company Information
 Table 111. GlaxoSmithKline (GSK) Description and Business Overview
 Table 112. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product
 Table 114. GlaxoSmithKline (GSK) Recent Developments/Updates
 Table 115. Amgen Company Information
 Table 116. Amgen Description and Business Overview
 Table 117. Amgen Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Amgen Influenza (Flu) Antiviral Drugs Product
 Table 119. Amgen Recent Developments/Updates
 Table 120. AstraZeneca Company Information
 Table 121. AstraZeneca Description and Business Overview
 Table 122. AstraZeneca Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. AstraZeneca Influenza (Flu) Antiviral Drugs Product
 Table 124. AstraZeneca Recent Developments/Updates
 Table 125. Bristol-Myers Squibb Company Information
 Table 126. Bristol-Myers Squibb Description and Business Overview
 Table 127. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product
 Table 129. Bristol-Myers Squibb Recent Developments/Updates
 Table 130. Eli Lilly Company Information
 Table 131. Eli Lilly Description and Business Overview
 Table 132. Eli Lilly Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Eli Lilly Influenza (Flu) Antiviral Drugs Product
 Table 134. Eli Lilly Recent Developments/Updates
 Table 135. Teva Company Information
 Table 136. Teva Description and Business Overview
 Table 137. Teva Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Teva Influenza (Flu) Antiviral Drugs Product
 Table 139. Teva Recent Developments/Updates
 Table 140. Bayer Company Information
 Table 141. Bayer Description and Business Overview
 Table 142. Bayer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Bayer Influenza (Flu) Antiviral Drugs Product
 Table 144. Bayer Recent Developments/Updates
 Table 145. Novo Nordisk Company Information
 Table 146. Novo Nordisk Description and Business Overview
 Table 147. Novo Nordisk Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. Novo Nordisk Influenza (Flu) Antiviral Drugs Product
 Table 149. Novo Nordisk Recent Developments/Updates
 Table 150. Allergan Company Information
 Table 151. Allergan Description and Business Overview
 Table 152. Allergan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Allergan Influenza (Flu) Antiviral Drugs Product
 Table 154. Allergan Recent Developments/Updates
 Table 155. Takeda Company Information
 Table 156. Takeda Description and Business Overview
 Table 157. Takeda Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. Takeda Influenza (Flu) Antiviral Drugs Product
 Table 159. Takeda Recent Developments/Updates
 Table 160. Boehringer Ingelheim Company Information
 Table 161. Boehringer Ingelheim Description and Business Overview
 Table 162. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product
 Table 164. Boehringer Ingelheim Recent Developments/Updates
 Table 165. Teva Pharmaceutical Industries Company Information
 Table 166. Teva Pharmaceutical Industries Description and Business Overview
 Table 167. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 168. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product
 Table 169. Teva Pharmaceutical Industries Recent Developments/Updates
 Table 170. Mylan Company Information
 Table 171. Mylan Description and Business Overview
 Table 172. Mylan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 173. Mylan Influenza (Flu) Antiviral Drugs Product
 Table 174. Mylan Recent Developments/Updates
 Table 175. F. Hoffmann-La Roche Company Information
 Table 176. F. Hoffmann-La Roche Description and Business Overview
 Table 177. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 178. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product
 Table 179. F. Hoffmann-La Roche Recent Developments/Updates
 Table 180. Bristol-Myers-Squibb Company Information
 Table 181. Bristol-Myers-Squibb Description and Business Overview
 Table 182. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 183. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product
 Table 184. Bristol-Myers-Squibb Recent Developments/Updates
 Table 185. Aurobindo Pharma Company Information
 Table 186. Aurobindo Pharma Description and Business Overview
 Table 187. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 188. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product
 Table 189. Aurobindo Pharma Recent Developments/Updates
 Table 190. Cipla Company Information
 Table 191. Cipla Description and Business Overview
 Table 192. Cipla Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 193. Cipla Influenza (Flu) Antiviral Drugs Product
 Table 194. Cipla Recent Developments/Updates
 Table 195. Key Raw Materials Lists
 Table 196. Raw Materials Key Suppliers Lists
 Table 197. Influenza (Flu) Antiviral Drugs Distributors List
 Table 198. Influenza (Flu) Antiviral Drugs Customers List
 Table 199. Influenza (Flu) Antiviral Drugs Market Trends
 Table 200. Influenza (Flu) Antiviral Drugs Market Drivers
 Table 201. Influenza (Flu) Antiviral Drugs Market Challenges
 Table 202. Influenza (Flu) Antiviral Drugs Market Restraints
 Table 203. Research Programs/Design for This Report
 Table 204. Key Data Information from Secondary Sources
 Table 205. Key Data Information from Primary Sources
 Table 206. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Influenza (Flu) Antiviral Drugs
 Figure 2. Global Influenza (Flu) Antiviral Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Influenza (Flu) Antiviral Drugs Market Share by Type: 2024 & 2031
 Figure 4. Penetration and Dehulling Inhibitors Product Picture
 Figure 5. DNA Polymerase Inhibitors Product Picture
 Figure 6. Reverse Transcriptase Inhibitors Product Picture
 Figure 7. Protein Inhibitors Product Picture
 Figure 8. Neuraminidase Inhibitors Product Picture
 Figure 9. Broad-spectrum Antiviral Drugs Product Picture
 Figure 10. Global Influenza (Flu) Antiviral Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2024 & 2031
 Figure 12. Hospital
 Figure 13. Clinic
 Figure 14. Household
 Figure 15. Others
 Figure 16. Global Influenza (Flu) Antiviral Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Influenza (Flu) Antiviral Drugs Market Size (2020-2031) & (US$ Million)
 Figure 18. Global Influenza (Flu) Antiviral Drugs Sales (2020-2031) & (K Units)
 Figure 19. Global Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 20. Influenza (Flu) Antiviral Drugs Report Years Considered
 Figure 21. Influenza (Flu) Antiviral Drugs Sales Share by Manufacturers in 2024
 Figure 22. Global Influenza (Flu) Antiviral Drugs Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest Influenza (Flu) Antiviral Drugs Players: Market Share by Revenue in Influenza (Flu) Antiviral Drugs in 2024
 Figure 24. Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global Influenza (Flu) Antiviral Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2020-2031)
 Figure 27. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. U.S. Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2020-2031)
 Figure 31. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2020-2031)
 Figure 32. Germany Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2020-2031)
 Figure 39. China Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Taiwan Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Indonesia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Thailand Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Malaysia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Philippines Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Influenza (Flu) Antiviral Drugs by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Influenza (Flu) Antiviral Drugs by Type (2020-2031)
 Figure 61. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Influenza (Flu) Antiviral Drugs by Application (2020-2031)
 Figure 63. Global Revenue Market Share of Influenza (Flu) Antiviral Drugs by Application (2020-2031)
 Figure 64. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 65. Influenza (Flu) Antiviral Drugs Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Antivirals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Influenza Therapeutics Market Insights Forecast to 2030
Influenza Antiviral Drugs Market
Global Antiviral Drugs for Influenza Market Research Report 2025
Global Cold and Flu Drugs Market Insights Forecast to 2030
Antiviral Drug Packaging Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antiviral Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti Influenza Virus Chinese Medicine Market Research Report 2024
Global Oseltamivir Market Insights Forecast to 2030
Anti influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Novel Antiviral Drugs Market
Global Infectious Disease Drugs Market Insights Forecast to 2030
Antiviral Drug Resistance Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ophthalmic Antivirals Market Research Report 2025
Antiviral Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hepatic Antiviral Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tamiflu Oseltamivir Phosphate Market Insights Forecast to 2030
Global Antiviral Microbial Drugs Market Research Report 2024
Direct acting Antiviral Drugs Market
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions